Completed PHASE1 INTERVENTIONAL 7-arm NCT03278470

A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject

A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximum Tolerable Dose After Single Oral Dose of HL237 in Healthy Male Subject

Sponsor: Hanlim Pharm. Co., Ltd.

Conditions Rheumatoid Arthritis

Interventions HL237 Placebo Oral Tablet

Updated 7 times since 2017 Last updated: Aug 16, 2018 Started: Jun 26, 2017 Primary completion: Mar 19, 2018 Completion: Mar 19, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Hanlim Pharm. Co., Ltd. and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Enrolling By Invitation → Completed

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Enrolling By Invitation PHASE1
Oct 2017 — Jun 2018 [monthly]

Enrolling By Invitation PHASE1

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanlim Pharm. Co., Ltd.

Data source: Hanlim Pharm. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Soeul, South Korea